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Abstract
Background: The blood brain barrier (BBB) is the first line of defence of the central nervous
system (CNS) against circulating pathogens, such as HIV. The cytotoxic HIV protein, gp120,
damages endothelial cells of the BBB, thereby compromising its integrity, which may lead to
migration of HIV-infected cells into the brain. Fibroblast growth factor 2 (FGF2), produced
primarily by astrocytes, promotes endothelial cell fitness and angiogenesis. We hypothesized that
treatment of human umbilical vein endothelial cells (HUVEC) with FGF2 would protect the cells
from gp120-mediated toxicity via endothelial cell survival signalling.
Results: Exposure of HUVEC to gp120 resulted in dose- and time-dependent cell death; whereas,
pre-treatment of endothelial cells with FGF2 protected cells from gp120 angiotoxicity. Treatment
of HUVEC with FGF2 resulted in dose- and time-dependent activation of the extracellular
regulated kinase (ERK), with moderate effects on phosphoinositol 3 kinase (PI3K) and protein
kinase B (PKB), also known as AKT, but no effects on glycogen synthase kinase 3 (GSK3β) activity.
Using pharmacological approaches, gene transfer and kinase activity assays, we show that FGF2-
mediated angioprotection against gp120 toxicity is regulated by crosstalk among the ERK, PI3K-
AKT and PKC signalling pathways.
Conclusions: Taken together, these results suggest that FGF2 may play a significant role in
maintaining the integrity of the BBB during the progress of HIV associated cerebral endothelial cell
damage.
Background
Maintenance of blood brain barrier (BBB) integrity is crit-
ical to prevent the passage of potentially harmful factors,
such as pathogens or toxins into the brain. During the
progression of central nervous system (CNS) infectious
disease, pathogens might gain access to the brain by com-
promising the integrity of the BBB. In the course of AIDS,
HIV enters the brain at early stages, disrupting the compo-
nents of the BBB resulting in a chronic state of inflamma-
tion known as HIV encephalitis (HIVE) [1,2]. HIVE is
characterized by the presence of HIV-infected microglia
and / or macrophages in the brain, the formation of
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gliosis and myelin pallor, the combined effects of which
could result in cognitive impairment [3]. Because
endothelial cells of the BBB provide the first point of con-
tact between blood-borne viral products and the brain,
they provide the front line of defence against viral entry
into the CNS. Alterations in signalling between compo-
nents of the BBB with either HIV proteins or factors pro-
duced in response to HIV infection, such as cytokines and
chemokines, may disrupt BBB integrity, resulting in a
compromise that could promote transmigration of acti-
vated monocytes or HIV infected cells into the brain. Toxic
viral products released by HIV-infected cells such as,
gp120, Tat or Nef, together with cytokines and chemok-
ines from activated monocytes, can act to increase BBB
permeability [4-8].
Cell-free gp120 is found in the serum of HIV infected
patients and crosses the BBB by absorptive endocytosis [9]
and has been detected in the perivascular regions of the
brain [10]. Gp120 is toxic to uninfected cells such as cere-
bral endothelial cells [8], and induces numerous signal-
ling alterations in glial cells leading to indirect neuronal
dysfunction and death [11,12]. Huang et al. have shown
that gp120 promotes apoptosis in human umbilical vas-
cular endothelial cells (HUVEC) by acting through
CXCR4 and CCR5 chemokine receptors to increase activa-
tion of protein kinase (PKC) [13,14]. Furthermore, these
studies show that the toxic effects of gp120 were blocked
by PKC antagonists, sphingosine, phorbol esters and
fibroblast growth factor 2 (FGF2) [13].
While viral products and inflammatory response proteins
may damage components of the BBB, other factors, such
as growth factors, may work to preserve BBB integrity
through maintaining endothelial cell fitness. In this con-
text, FGF2 is of particular interest for several reasons. First,
FGF2 is produced primarily by astrocytes that are in prox-
imity to cerebral endothelial cells in the blood brain bar-
rier [15]. Among the known astrocyte-derived growth
factors, only FGF2 mimics the signalling actions of astro-
cytes to the BBB [15,16]. Second, of the four FGF receptors
(FGFR), FGFR1 is mainly expressed on neurons and
endothelial cells while FGFR2 and FGFR3 are found on
glial cells [17-19]. FGF2, which binds to FGFR1, exhibits a
wide range of angiotrophic effects [15,16] and promotes
the survival of cortical and hippocampal neurons
[15,16,20-22]. Third, FGF2 signals through FGFR1 and
activates phosphoinositol 3 kinase (PI3K), protein kinase
C (PKC), extracellular regulated kinase (ERK), and p38
pathways [23-25]. Both ERK and p38 belong to the
mitogen-activated protein kinase (MAPK) signalling path-
ways and have been shown to be involved in regulating
endothelial cell survival [15,16]. FGF2 protection of
HUVEC from gp120 is proposed to occur by preventing
the gp120-mediated increase in PKC activity [13], how-
ever, protective signalling mechanisms directly induced
by FGF2 have not been addressed. Therefore, we investi-
gated the signalling pathways involved in FGF2-mediated
protection against gp120 toxicity in HUVEC. Our studies
indicate that FGF2 protects endothelial cells from gp120-
mediated toxicity by crosstalk among several signalling
pathways downstream of the tyrosine kinase FGFR. These
pathways include, the ERK, PI3K/AKT and PKC signalling
cascades. Likewise, other studies have suggested that sig-
nalling pathways that inhibit cell death (e.g., p38, MAPK/
ERK) and survival pathways (e.g., AKT/PKB) may repre-
sent the next investigational step in inhibition of HIV-
related CNS toxicity [26]. In this context, FGF2-mediated
signalling may play an important role in maintaining BBB
integrity during HIV trafficking into the brain and/or cell-
free gp120 interactions with cerebral endothelial cells.
Results
FGF2 protects endothelial cells from gp120-mediated 
toxicity
Consistent with previous reports [13,14,27,28], our
results showed that gp120 (25 ng/ml) increased cell death
of HUVEC above control by approximately 27.5% (aver-
age of results from all viability assays) after 24 h exposure
(Fig. 1) as determined by Trypan Blue Exclusion, TUNEL,
and FA/PI staining (Fig. 1E, J, O, respectively). However,
cells pre-treated with FGF2 (20 ng/ml) for 24 h and then
exposed to gp120 displayed essentially the same percent-
age of cell death as untreated control cells (Fig. 1D, E, I, J,
N, O). Although FGF2 treatment of HUVEC most likely
improved overall cell fitness [15,16], no significant differ-
ences in the total numbers of cells (Fig. 2A) or in cell via-
bility were observed between control and FGF2 treated
cultures (Fig. 1E, J, O and 2B). Furthermore, time course
experiments indicated that simultaneous treatment (data
not shown) or pre-treatment with FGF2 up to 24 h was
effective at protecting cells from gp120 toxicity (Fig. 2B).
These results indicate that FGF2 is protective against
gp120-mediated toxicity in HUVEC.
FGF2 activates ERK in HUVEC
To explore mechanisms involved in the angio-protective
effects of FGF2 against gp120, we first investigated FGF2-
stimulated signalling mechanisms that are involved in cell
survival pathways. The binding of FGF2 to its receptor
(FGFR1) induces several signalling cascades, such as
MAPK-mediated ERK activation and AKT-mediated
GSK3β inactivation, both of which regulate cell survival.
We first determined the effects of FGF2 stimulation on
phosphorylation of ERK and GSK3β in time course exper-
iments in HUVEC (Fig. 3, lanes 1–3). Western blot analy-
sis showed that HUVEC treated with FGF2 (20 ng/ml)
resulted in maximum ERK phosphorylation 5–10 min
after stimulation (Fig. 3A, lanes 1–3), followed by aPage 2 of 15
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min (data not shown), with no effect on levels of total
ERK (Fig. 3B, lanes 1–3). Neither GSK3β (Fig. 3C) nor
PKC (data not shown) phosphorylation was affected by
FGF2 treatment.
To test the specificity of FGF2 on signalling, HUVEC were
exposed to pharmacological inhibitors for PI3K
(LY294002), ERK (U0126), and PKC (Bis I and Gö6983)
for 30 min prior to FGF2 treatment (Fig. 3A, lanes 4–7,
respectively). ERK phosphorylation was inhibited by
blocking ERK and PKC (Fig. 3, lanes 5–7). Interestingly,
blocking the PI3K/AKT/GSK3β pathway resulted in a dra-
matic increase in ERK phosphorylation (Fig. 3A, lane 4).
Neither FGF2 nor inhibitors affected levels of total ERK
(Fig. 3B). With regard to GSK3β, blocking PI3K with
LY294002 and PKC with Bis I or Gö6983 also inhibited
GSK3β phosphorylation (Fig. 3C, lanes 4, 6, 7), albeit to
a lesser degree. Treatment with the ERK inhibitor U0126
increased GSK3β phosphorylation (Fig. 3C, lane 5). Nei-
ther FGF2 nor inhibitors affected total levels of PI3K or
GSK3β (Fig. 3D, E). These inhibitor studies suggest that
FGF2 signalling involves crosstalk between PI3K/AKT/
GSK3β and ERK that is possibly mediated by PKC (Fig. 3A,
lane 4 and 3C, lane 5).
To further confirm that these changes in kinase signalling
are mediated by FGF2, immuno-complex kinase assays
were performed (Fig. 4A, B). As indicated by an astrisk (*)
in Fig. 4A, lane 2, FGF2 treatment increased ERK activity
significantly above levels observed in un-treated control
cells (Fig. 4A). Likewise, and as shown in Figure 3, FGF2-
mediated ERK activity was significantly greater than con-
trol in the presence of the PI3K inhibitor LY294002 (Fig.
Cell viability assays for FGF2 protection of HUVEC against gp120-mediated toxicityFigure 1
Cell viability assays for FGF2 protection of HUVEC against gp120-mediated toxicity (A-D) Phase contrast, (F-I) 
TUNEL staining, and (K-O) fluorescent staining of HUVEC. Panels A, F, and K show images of untreated HUVEC control; B, G, 
and L show HUVEC treated for 24 h with FGF2 (20 ng/ml); panels C, H, and M show HUVEC treated for 24 h with gp120 (25 
ng/ml) and panels D, I, and N show HUVEC pre-treated with FGF2 for 24 h before a 24 h exposure to gp120. Panels E, J and O 
show the percentage of cell death as determined by Trypan blue exclusion, percentage of DNA fragmentation by TUNEL and 
FA/PI staining, respectively. Results shown in panels E, J and O represent the average of three separate experiments performed 
in triplicate. * = P < 0.05 by One-Way ANOVA with post-hoc Dunnett's when compared to control. Bar = 20 microns.Page 3 of 15
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inhibitors Bis I and Gö6983 significantly blocked FGF2-
mediated ERK activity (Fig. 4A, D) as shown in Figure 3.
Conversely, FGF2 alone or in the presence of the inhibi-
tors LY294002, Bis I and Gö6983 had minimal effects on
GSK3β activity (Fig 4B, D). However, the ERK inhibitor
U0126 significantly decreased GSK3β activity (Fig. 4B).
PD98059 also decreased GSK3β activity although at statis-
tically insignificant levels (Fig. 4B). Cell viability was not
significantly affected by FGF2 or inhibitor treatments (Fig.
4C) ensuring that effects of inhibitors on kinase activity
were not due to cell death.
Taken together these data show that FGF2 activates ERK
signalling in HUVEC but has little effect on GSK3β activity
unless FGF2-mediated ERK phosphorylation is blocked.
Furthermore, independently of FGF2, PI3K/AKT and PKC
signalling is necessary for GSK3β phosphorylation. How-
ever, once GSK3β is phosphorylated, the kinase activity of
GSK3β is independent of PI3K/AKT and PKC downstream
signalling. On the other hand, GSK3β phosphorylation is
influenced, to some degree, by FGF2-mediated ERK phos-
phorylation since blocking ERK phosphorylation results
in a significant increase in the phosphorylation of GSK3β.
Likewise, the kinase activity of GSK3β also appears to
require ERK phosphorylation for maximal activation. In
summary, the FGF2-mediated kinase activity of ERK and
GSK3β appears to involve crosstalk between these path-
ways and possibly PKC. The potential roles of ERK and
GSK3β phosphorylation and activity in FGF2-mediated
protection from gp120 were investigated.
FGF2 angioprotection in HUVEC against gp120 toxicity is 
mediated, in part, by ERK signalling
To investigate the potential role of ERK and PI3K/AKT/
GSK3β signalling in FGF2-mediated angioprotection
against gp120, HUVEC were treated with LY294002,
U0126, Bis I, or Gö6983 for 30 min prior to FGF2 and
gp120 exposure (Fig. 5). Results from cell toxicity assays
determined by Trypan blue exclusion (Fig. 5A), support
our previous data (Fig. 1) showing that exposure to gp120
alone significantly increased cell death above control and
FGF2 treated cells; whereas, cells pre-treated with FGF2
before exposure to gp120 were protected (Fig. 5). The pro-
tective effects of FGF2 against gp120 were significantly
blocked by U0126, which inhibits MEK to block ERK
phosphorylation, (Fig. 5A). Blocking PI3K with LY
294002 partially blocked FGF2 protection, although at
levels insignificant from control. FGF2 protection from
gp120 was not affected by blocking PKC with Bis I or
Gö6983 (Fig. 5A). Treating cells with U0126 to block ERK
phosphorylation, and gp120 in the absence of FGF2
resulted in significant cell death compared to untreated
cells (Fig. 5B). Moreover, pre-incubation of FGF2 with
Effects of FGF2 and gp120 on cell proliferation and viabilityFigure 2
Effects of FGF2 and gp120 on cell proliferation and viability A) Density of proliferating HUVEC exposed to FGF2 and/
or gp120. B) Cell viability of cells exposed to gp120 after pre-treating HUVEC with FGF2 for different lengths of time. Cell via-
bility was measured 24 h after gp120 addition. * = P < 0.05 by One-Way ANOVA with post-hoc Dunnett's when compared to 
control.Page 4 of 15
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ated angioprotection against gp120 (Fig. 5B). These
results indicate that ERK phosphorylation is significantly
involved in FGF2-mediated angioprotection from gp120.
PI3K/AKT/GSK3β signalling is partially involved in FGF2
protection from gp120; whereas, PKC signalling in the
presence of FGF2 is not necessary for protection from
gp120. These results suggest that FGF2 protects endothe-
lial cells from gp120 largely by ERK stimulation with a
partial contribution by GSK3β phosphorylation.
To further confirm the contribution of these signalling
pathways in FGF2 protection against gp120, HUVEC
infected with caERK or caAKT were exposed to gp120 and
assayed for cell viability. As expected, endothelial cells
infected with caERK and exposed to gp120 were signifi-
cantly protected from gp120 toxicity (Fig. 6). caAKT con-
veyed only partial protection from gp120 toxicity, less
than either caERK or FGF2 treatment (Fig. 6). In control
experiments where HUVEC were infected with GFP aden-
ovirus, no protective effects against gp120 were observed
(Fig. 6). Furthermore, none of the adenoviral constructs
alone promoted significant cell toxicity (Fig. 6). In agree-
ment with our previous data, these results suggest that
ERK activation plays a significant role in protection of
endothelial cells from gp120, and AKT/GSK3β is also be
involved.
To confirm that the gene transfer approach resulted in
ERK and AKT phosphorylation and kinase activation,
Western blot (Fig. 7A–D) and immuno-complex assays
(Fig. 7E, F) were performed. ERK kinase activity was
detected using an antibody that recognizes only the phos-
phorylated form of ERK1/2. Consistent with our previous
experiments (Fig. 3A), FGF2 stimulation resulted in an
increase of both ERK1 (44 kDa) and ERK2 (42 kDa) phos-
phorylation (Fig. 7A). Levels of FGF2-mediated phospho-
rylation of ERK2 were greater than ERK1 (Fig. 7A, lane 2).
Infection with the GFP adenoviral construct alone had no
effect on ERK1/2 phosphorylation (Fig. 7A, lane 3). In
contrast, infection with caERK resulted in a significant
increase in ERK1 phosphorylation with no effect on ERK2
(Fig. 7A, lane 5). FGF2 treatment in combination with
caERK induced high levels of ERK1 phosphorylation with
only moderate increases in ERK2 phosphorylation (Fig.
7A, lane 6). These results indicate that FGF2 stimulation
results in phosphorylation of mainly ERK2; whereas gene
transfer of caERK or the combination of FGF2 and caERK
mainly increased ERK1 phosphorylation. Importantly,
total ERK activity levels were similar in caERK with or
without FGF2 (Fig. 7E and 7F). Moreover, the level of pro-
tection conveyed by FGF2 alone was similar to protection
by caERK or caERK plus FGF2.
On the other hand, caAKT alone had no effect on ERK1/2
phosphorylation (Fig. 7A, lane 7), whereas, FGF2 treat-
ment in combination with caAKT (Fig. 7A, lane 8) had
similar effects on ERK1/2 phosphorylation as observed
with FGF2 (lane 2) alone or with GFP and FGF2 (lane 4).
Levels of total ERK were not affected by FGF2, GFP, caERK
or caAKT (Fig. 7B). Infection of HUVEC with caAKT
resulted in a slight increase in baseline levels of AKT phos-
phorylation (Fig. 7C, lane 7). Levels of total AKT were not
affected by FGF2, GFP, caERK, or caAKT (Fig. 7D). Con-
sistent with Western blot analyses, immunocomplex
assays show that caERK and/or FGF2 increased levels of
ERK activity (Fig. 7E, lanes 2–4, 6 and 7F), whereas nei-
ther caAKT nor GFP resulted in increased ERK activity in
the absence of FGF2 (Fig. 7E lanes 5, 7 and Fig. 7F).
Results from inhibitor studies (Fig. 5) and gene transfer
experiments (Fig. 6) suggest that both ERK and PI3K/AKT
(albeit to a lesser degree) are involved in FGF2-mediated
protection against gp120 toxicity. Furthermore, blocking
the ERK-mediated pathway results in an increase in
GSK3β phosphorylation and vice versa: blocking the AKT/
GSK3β pathway after FGF2 stimulation results in an
increase in ERK phosphorylation. These results suggest
Effects of inhibitors on FGF2-mediated ERK activationFigure 3
Effects of inhibitors on FGF2-mediated ERK activa-
tion A) Western blot (WB) reacted with anti-phospho-ERK 
after treatment with FGF2 for 0, 5, 10 min (lanes 1–3) and 
after inhibitors LY294002 (to block PI3K), U0126 (to block 
MEK), and Bis I and Gö6983 (to block PKC) (lanes 4–7, 
respectively). B) WB reacted with anti-total ERK antibody. 
(C) WB reacted with anti-phospho-GSK3β. D) WB reacted 
with anti-GSK3β. E) WB reacted with anti-PI3K antibody. 
The same WB was used in each experiment after stripping, 
reblocking and incubating with new antibodies for the given 
protein.Page 5 of 15
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may mediate protection that involves crosstalk between
the ERK and PI3K pathways (Fig. 3A and 3C, and Fig. 6).
Moreover, inhibitor studies suggest PKC may be involved
in this signalling convergence, but a direct role of PKC in
FGF2 protection against gp120 is unclear.
PKC may be involved in crosstalk between ERK and AKT 
signalling pathways during FGF2 protection from gp120
Our studies using pharmacological inhibitors suggest that
PKC may be involved in a crosstalk mechanism observed
between the ERK and AKT/GSK3β pathways in FGF2 sig-
nalling. For example, when HUVEC were exposed to PKC
inhibitors Bis I and Gö6983 prior to FGF2 treatment, ERK
phosphorylation was inhibited to below baseline levels,
showing that FGF2-mediated ERK phosphorylation is at
least in part influenced by PKC phosphorylation (Fig. 3A,
lanes 6 and 7). Likewise, PKC inhibitors partially
inhibited GSK3β phosphorylation after FGF2 stimulation
(Fig. 3C, lanes 6 and 7). Furthermore, since Huang et al.
have shown that total PKC phosphorylation increases
with gp120 treatment in HUVEC and that FGF2 is protec-
tive [13], we explored the possibility that similar crosstalk
might be involved in the FGF2-mediated protection from
gp120. To address these signalling events, we determined
which signalling pathways were initiated by FGF2 and
which were initiated by gp120.
To differentiate the effects of gp120 on ERK, GSK3β and
PKC phosphorylation from those obtained in Fig. 3 where
FGF2 alone was utilized, we treated endothelial cells with
1) gp120 alone (Fig. 8A, C), 2) gp120 in combination
with inhibitors (Fig. 8A, C), and 3) inhibitors, FGF2 and
gp120 (Fig. 8B, C). Treatment of endothelial cells with
gp120 alone (Fig. 8A, lane 2, 8C) or with inhibitors alone
(data not shown) did not change levels of ERK phospho-
rylation. However, when endothelial cells were treated
with LY204002 and then exposed to gp120 for 30 min, a
significant increase in ERK phosphorylation was observed
(Fig. 8A, lane 3, 8C). Furthermore, in the presence of both
FGF2 and gp120 and the inhibitor LY294002, ERK phos-
phorylation also increased (Fig. 8B, lane 3, 8C). Interest-
ingly, in the presence of the PKC inhibitor that includes
inhibition of the ζ isoform (Gö6983), ERK phosphoryla-
tion is returned to approximately control levels (Fig. 8A–
B, lane 5, 8C). On the other hand, inhibition of the classic
Effects of inhibitors on FGF2-stimulated ERK and GSK3β activityFigure 4
Effects of inhibitors on FGF2-stimulated ERK and GSK3β activity Immunocomplex kinase assays for (A) ERK and (B) 
GSK3β activity without FGF2 treatment, or after inhibition with PD98059, U0126, LY29004, Bisindolymaleimide I or Gö6983 
followed by FGF2 treatment. (C) Inhibitor treatment alone. (D) Summary of changes in phosphorylation (P) versus changes in 
activity (Act) of ERK and GSK3β. ⇑ Indicates an increase, ‡ indicates a decrease, – indicates no change. * = P < 0.05 by One-
Way ANOVA with post-hoc Dunnett's when compared to control.Page 6 of 15
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blocks ERK phosphorylation in the presence of FGF2 and
gp120 (Fig. 8B, lane 4), as does inhibition of ERK phos-
phorylation with U0126 (Fig. 8B, lane 6). These results
suggest that PKC signalling may be involved in FGF2-
stimulated ERK phosphorylation that protects against
gp120. Treatment of HUVEC with gp120 alone, or with
gp120 and inhibitors to block ERK, or PI3K/AKT/GSK3β
had little effect on GSK3β phosphorylation (Fig. 8A, lanes
1–3, 6, 8C); whereas, blocking PKC decreased levels of
GSK3β phosphorylation (Fig. 8A, lanes 4 and 5). Like-
wise, treatment of HUVEC with FGF2 alone or with FGF2,
gp120 and inhibitors to block PI3K/AKT/GSK3β or ERK
had little effect on GSK3β phosphorylation (Fig. 8B, lanes
1–3, 6, 8C); whereas, blocking PKC decreased levels of
GSK3β phosphorylation (Fig. 8B, lanes 4 and 5, 8C). In
summary, in the presence of FGF2 and inhibitors for
FGFR and PI3K/AKT/GSK3β, ERK phosphorylation
increases (Fig. 3A). However, in the presence of FGF2 or
FGF2 and inhibitors for PKC or ERK, ERK phosphoryla-
tion decreases (Fig 8A, B, C). Likewise, PKC inhibitors
almost completely abolish GSK3β phosphorylation in the
presence of gp120, independently of FGF2 stimulation
(Fig. 8B, C). Together, these findings point to PKC
involvement with FGF2 stimulated signalling in HUVEC
during challenge with gp120, however further
experimentation is needed to confirm any role of PKC in
FGF2-mediated protection from gp120.
Discussion
The present study is the first to show that FGF2 protects
HUVEC against the toxic effects of gp120 via crosstalk of
the ERK-PI3K/AKT pathways (Fig. 9). Consistent with
these finding, FGF2 has been shown to protect endothe-
lial cells from oxidative stress [29] and radiation [30,31].
These studies suggest that PKC is involved in protection
against ultra-violet radiation, since blocking PKC abro-
gates FGF2-mediated protection [31]. Similarly, a recent
study showed that FGF2 also protected endothelial cells
from gp120-mediated toxicity that was induced by dysreg-
ulation of PKC activity to promote apoptosis [13,28];
however, the pathways by which FGF2 protected
Viability assays indicate that ERK activation is required for FGF2 protection against gp120F gure 5
Viability assays indicate that ERK activation is required for FGF2 protection against gp120 (A) Trypan Blue Exclu-
sion assay for cell survival after 30 min of treatment with inhibitors LY294002, U0126, Bis I, or Gö6983 followed by treatment 
with FGF2 and/or gp120. (B) Trypan Blue Exclusion assay for cell survival after 30 min of treatment with the MEK inhibitor 
U0126 alone, and followed by exposure to gp120 and/or FGF2 for 24 h. In cells treated with FGF2 and anti-FGF2, HUVEC 
were exposed to anti-FGF2 antibody for 1 h followed by treatment with FGF2 alone or in combination with gp120. * Indicates 
a significant difference from control. * = P < 0.05 by One-Way ANOVA with post-hoc Dunnett's when compared to control.Page 7 of 15
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be represented by independent mechanisms. Therefore,
our study focused on signalling pathways involved in
angioprotection upon exposure to gp120. gp120 has been
reported to dysregulate PKC signalling but also to induce
ERK phosphorylation in several systems by different path-
ways [32-34]. Likewise, our studies suggest that gp120
and FGF2 signalling in HUVEC may, in some aspects,
overlap and involve primarily ERK and to a lesser extent
AKT/GSK3β signalling. In this context, when HUVEC were
treated with the ERK inhibitor U0126, then exposed to
gp120, a significant increase in cell death above control
was observed; however, the amount of cell death observed
under these conditions was less than that observed in cells
treated with gp120 alone. In HUVEC, PKC phosphoryla-
tion does not change when stimulated with FGF2 and
PKC does not appear to be directly involved in FGF2-
mediated protection from gp120 since inhibitors of this
pathway had no effect on angioprotection. However, pre-
vious studies have shown that PCK may play a role in the
MAPK signalling cascade, through upstream crosstalk
with Ras (Figure 9) [35,36]. Moreover, in the presence of
gp120 with or without FGF2, both ERK and PKC inhibi-
tors completely block ERK phosphorylation, suggesting
that while PKC is involved in ERK phosphorylation, the
protective properties of ERK are not dependent on PKC. In
support of these conclusions, the current study shows that
inhibition of ERK, and to a lesser degree PI3K/AKT, blocks
FGF2-mediated protection from gp120. Our data suggest
that FGF2 signalling via ERK-PI3K/AKT crosstalk is
responsible for protection of endothelial cells from
gp120. Other mechanisms that could contribute to FGF2-
mediated protection against gp120 may include, but are
not limited to, interaction of FGF2 with heparin sulfate
receptors and/or stimulation of alternative pathways not
involving ERK [37].
Consistent with these findings, FGF2 protects cardiac
myocytes from inducible nitric oxide synthetase induced
apoptosis by the ERK signalling pathway [38], and in neu-
ronal cells FGF2-mediated ERK activation is essential for
survival signalling [39]. Our studies provide evidence for
the first time that FGF2-mediated protection of endothe-
lial cells against gp120 toxicity largely occurs through an
ERK-dependent pathway. Our data also suggest crosstalk
between the PI3K/AKT and ERK pathways, since blocking
PI3K resulted in a significant increase in ERK phosphor-
ylation in FGF2 treated endothelial cells. Likewise, block-
ing ERK caused an increase in phosphorylation of GSK3β,
which is directly downstream of PI3K/AKT signalling. In
this context, it is possible that upon stimulation by growth
factors such as FGF2, endothelial cells utilize several sig-
nalling cascades that are capable of crosstalk to promote
cell fitness and survival, as suggested by studies involving
vascular endothelial growth factor (VEGF) signalling in
the presence or absence of serum [40]. In these studies, it
was shown that crosstalk between the AKT and p38 path-
ways may regulate cell survival during serum withdrawal
and VEGF stimulation [40]. Our studies also point toward
signalling crosstalk during FGF2 protection from gp120.
Crosstalk between PI3K and p38 was shown to be medi-
ated by MAPK kinase kinase (MEKK3) in VEGF signalling
[40]. Likewise, in FGF2 signalling, crosstalk between
PI3K/AKT and ERK might be mediated by PKC [41]. This
is consistent with previous studies showing that in VEGF-
stimulated endothelial cells, inhibition of PI3K resulted in
an increase in the phosphorylation of ERK1/2 and p38
phosphorylation [42]. Together with the findings in this
study, these reports emphasize the importance of different
signalling pathways communicating to regulate intracel-
lular signal transduction in endothelial cell survival
[43,44].
The observations reported in this study have potential
importance to the maintenance of BBB integrity in host
Gene transfer of constitutively active ERK and AKT protect cells from gp120 t xicityFigure 6
Gene transfer of constitutively active ERK and AKT 
protect cells from gp120 toxicity (A) After gene trans-
fer of constitutively active (ca) ERK or ca AKT, HUVEC were 
exposed to gp120, FGF2 or a combination of both and cell 
viability was assayed via Trypan Blue Exclusion. Controls 
consisted of ca ERK, ca AKT and GFP gene transfer without 
further treatment. * indicates a significant difference from 
control. ** indicates a significant difference from *. * = P < 
0.05 by One-Way ANOVA with post-hoc Dunnett's when 
compared to control. ** = P < 0.05 by One-Way ANOVA 
with post-hoc Tukey-Kramer when compared between 
experimental groups.Page 8 of 15
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astrocytes in close proximity to endothelial cells of the
BBB and functions to improve cell fitness and barrier
integrity. In in vitro models of the BBB, FGF2 treatment of
endothelial cells mimics the effects of astrocyte co-culture
by improving tight junction integrity [15]. Numerous
studies have shown that disruption of this key component
in the BBB is central to HIV infection of the CNS and is a
hallmark of HIVE [45]. This is particularly important dur-
ing HIV trafficking into the CNS because endothelial cells
of the BBB are the first neural cells to come in contact with
HIV infected cells or HIV products. Regulation among sig-
nalling crosstalk in endothelial cells by FGF2 is important
since these are the cells of the BBB that first encounter
HIV-infected and/or activated cells and HIV products such
as gp120. Migration of HIV-infected and/or activated cells
into the brain is largely regulated by endothelial cell integ-
rity. During the progression of HIVE, activated and HIV-
infected monocytes produce cytokines and chemokines
and release HIV products that act in concert to
compromise the integrity of the BBB [46]. This triggers a
series of signalling events that may result in the alteration
of tight junction proteins, such as zona occludins, thereby
promoting migration of HIV-infected cells into the brain
parenchyma [45,47,48]. Alternatively, astroglial cells that
are also an important component of the BBB might pro-
duce trophic factors such as FGF2 in response to endothe-
lial cell distress in attempts to maintain BBB integrity.
Among them, factors produced by damaged endothelial
cells, including tissue factor, can induce the early growth
response-1 gene (Egr-1) transcription factor in astrocytes
that in turn directs expression of FGF2 [49].
Conclusions
In summary, the present study shows that FGF2 is protec-
tive against gp120 toxicity via crosstalk of ERK-PI3K/AKT
signalling pathways during compensatory signalling. This
finding is important for understanding the pathogenesis
of HIVE because factors produced by components of the
BBB, such as FGF2 by astrocytes, in response to toxins
such as HIV-gp120 may be responsible in part for angio-
protection of endothelial cells of brain microvasculature.
Methods
Cell culture
HUVEC (Clonetics®, BioWhittaker, Inc., Walkersville,
MD) were grown in complete media (endothelial basal
medium [EBM] supplemented with bovine brain extract
(12 µg/ml), human epithelial growth factor (10 ng/ml),
hydrocortisone (1 µg/ml), GA-1000 (Gentamicin and
Amphotericin B, 1 µg/ml) (Clonetics) and 20% fetal
bovine serum (Irvine Scientific, Irvine, CA). Complete
growth media were changed to minimal media (EBM, GA-
1000, 1% serum, Clonetics) for 24 h prior to treatments.
Effects of gene transfer of constitutively active ERK, AKT or GFP phosphorylationFigure 7
Effects of gene transfer of constitutively active ERK, AKT or GFP phosphorylation (A-D) Western Blot of HUVEC 
after treatment with FGF2, infected with the GFP, ca ERK or ca AKT adenoviral constructs, or treated with FGF2 and infected 
with adenoviral constructs. The same Western blot was used for all antibodies after stripping and rehybridizing. A) Reacted 
with anti-phospho ERK antibody (B) reacted with anti-total ERK antibody. (C) Reacted with anti-phospho AKT antibody. (D) 
Reacted with anti-total AKT antibody. (E) Immuno-complex assay showing changes in ERK activity with or without FGF2 
treatment in HUVEC with caERK, caAKT or GFP. (F) Quantification of ERK activity levels in HUVEC +/- FGF2 treatment with 
caERK, caAKT or GFP with the PhosphorImager as described in the Materials and Methods. * indicates a significant difference 
from control. * = P < 0.05 by One-Way ANOVA with post-hoc Dunnett's when compared to control.Page 9 of 15
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acterized this cell line with regard to FGF2 mediated
signaling responses and much of the work conducted in
the present study complements and builds on data from
these studies [13,27]. Furthermore, HUVEC mimic
numerous characteristics of cerebral endothelial cells.
Both short-term signaling events and long-term viability
of HUVEC were addressed after treatment with a combi-
nation of inhibitors, FGF2, and gp120, or with each com-
ponent alone, as described below.
HUVEC treatments to determine viability
For viability assays, HUVEC were treated with either 20
ng/ml FGF2, (Calbiochem, La Jolla, CA) or full-length
recombinant HIV-1BaL gp120 (25 ng/ml) NIH Research
and Reagent Program, Rockville, MD and Bartels-Mardx,
Carlsbad, CA) for 30 min, 1 h, 6 h, 12 h and 24 h. Recom-
binant HIV-1BaL used in these experiments is a macro-
phage trophic virus and binds to CD4 and signals via
CCR5. For protection assays, HUVEC were treated either
simultaneously with FGF2 and gp120 or pre-treated with
FGF2 for 30 min, 1 h, 6 h, 12 h and 24 h before the addi-
tion of 25 ng/ml gp120. HUVEC were harvested 24 h after
the addition of gp120 for viability assays.
Viability assays
For trypan blue exclusion assays, HUVEC were rinsed with
warm PBS, harvested, collected by gentle centrifugation,
resuspended in a PBS/ trypan blue solution (1:1, vol:vol)
and counted as previously described [50].
Terminal dUTP end labeling (TUNEL) staining was car-
ried out essentially as described previously [51,52]. Cells
were grown on coverslips, rinsed with PBS and fixed with
Effects of FGF2, gp120, and inhibitors on ERK and GSK3β phosphorylationFigure 8
Effects of FGF2, gp120, and inhibitors on ERK and GSK3β phosphorylation (A, B) Western blots showing ERK and 
GSK3β phosphorylation with (A) gp120 alone (lane 2), and with inhibitors (lanes 3–6), (B) FGF2 and gp120 (lane 2), and FGF2 
with inhibitors and gp120 (lanes 3–6). (C) Table summarizing data from western blots (A and B) showing changes in phospho-
rylation of ERK and GSK3β. ⇑ Indicates and increase, ‡ indicates a decrease, – indicates no change.Page 10 of 15
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After rinsing with PBS, cells were permeabilized with 1%
H2O2 in 1× PBS-Tween-20 for 10 min at room tempera-
ture, rinsed twice with PBS and air-dried for 2 min.
TUNEL was conducted according to the manufacturer's
instructions for staining (Roche Diagnostics, Indianapo-
lis, IN) and counterstained with Eosin Y. TUNEL positive
cells were detected with 3, 3' diaminobenzidine (DAB)
Diagrammatic representation of signalling pathways that may be involved in FGF2-mediated protection from gp120Figure 9
Diagrammatic representation of signalling pathways that may be involved in FGF2-mediated protection from 
gp120 As indicated by the diagram and as described by the data, it is possible that the crosstalk between the PI3K/AKT/
GSK3β and ERK pathways is mediated in part by PKC. PKC signalling also is reported to occur directly with PI3K and upstream 
of Ras. Furthermore, direct interaction between MEK and PKC downstream of Ras is reported. Likewise, ERK2 (p42) is 
reported to signal to Raf-1 via a positive feedback mechanism. The points of action of the inhibitors LY290042, U0126, Bisin-
dolymaleimide I, and Gö6983 are also shown.Page 11 of 15
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tem (Quantinet 570C, Leica, Bannockburn, IL).
Cell death was also assayed by fluorescent staining with
fluorescein diacetate (FA) and propidium iodide (PI) as
previously described [27]. The FA (Sigma) working solu-
tion was prepared by adding 10 µl of stock FA (50 mg FA
in 10 ml of acetone) to 2.5 ml PBS. The FA/PI (Sigma)
cocktail was prepared by adding 1 µl of FA working solu-
tion to 300 µl of PI (1 mg PI in 50 ml PBS). After rinsing
once in warm PBS, 20 µl of the FA/PI cocktail was added
to cells on coverslips and incubated 15 min in the dark.
Coverslips were placed cell-side up on SuperFrost slides
(Fisher Scientific, Pittsburgh, PA) under anti-fading media
(Vector Laboratories, Inc., Burlingame, CA) and immedi-
ately imaged with laser scanning confocal microscope
(LSCM, MRC1024, Bio-RAD, Hercules, CA).
HUVEC treatments for signalling events
Signalling events mediated by FGF2 and/or gp120 were
determined via Western Blot (WB) analyses. Cells were
treated with either 20 ng/ml FGF2 (Calbiochem, La Jolla,
CA) or gp120 for 30 min, 1 h, 6 h, 12 h and 24 h and ana-
lyzed by WB. Additionally, HUVEC were treated with
inhibitors alone. To test the effects of FGF2 stimulation or
gp120 exposure on downstream signalling, prior to FGF2
treatment, cells were pre-treated with inhibitors targeting
different steps in the MAPK, PKC or AKT/glycogen syn-
thase kinase 3-beta (GSK3β) pathways. For these experi-
ments, cells were incubated for 30 min with the: (i) 10 µM
PI3K inhibitor LY294002 (Calbiochem), (ii) 10 µM PKC
inhibitors Gö6983 (Calbiochem), 2 µM Bisindolymale-
imide I (Calbiochem), (iii) 10 µM MEK inhibitors U0126
or 20 µm PD98059 (Calbiochem). To test the specificity
of FGF2-mediated protection against gp120, HUVEC were
incubated with 20-fold excess anti-FGF2 neutralizing anti-
body prior to the addition of 20 ng/ml FGF2. Cells were
incubated in the presence of anti-FGF2 antibody and
FGF2 for 24 h, then exposed to 25 ng/ml gp120 for 24 h
and assayed for viability, ERK phosphorylation and kinase
activity. To determine the signalling events caused by
gp120, with or without FGF2 and inhibitors, the follow-
ing conditions were utilized: 1) cells were treated with
inhibitors for 30 min as previously described, and then
exposed to 25 ng/ml for 30 min, 2) inhibitors for 30 min
then gp120 for 30, 3) inhibitors for 30 min, FGF2 for 10
min and gp120 for 30 min. After treatments cells were
immediately harvested for Western analyses.
Western blot analysis in HUVEC
Briefly, after treatments, cell monolayers were harvested
and solubilized in HEPES homogenization buffer (1 mM
HEPES, 5 mM Benzamidine, 2 mM 2-Mercaptoethanol, 3
mM EDTA, 0.5 mM Magnesium Sulfate, 0.05% Sodium
Azide, Protease Inhibitor Cocktail III and Phosphatase
Inhibitor Cocktail I) (Calbiochem). Protein concentration
was determined by the method of Lowry and between 10–
15 µg of protein were separated by electrophoresis on
10% Bis-Tris NuPage Gels (Invitrogen, Carlsbad, CA).
Samples were then electroblotted onto Immunobilon P
nitrocellulose membranes (Millipore, Bedford, MA). Pro-
teins were immunolabeled with primary antibodies
against phosphoERK1/2 (1:2500) (Thr202/tyr204, mouse
monoclonal phosphoERK antibody) (Cell Signalling
Technology), total ERK1/2 (1:2500) (anti-mouse mono-
clonal ERK1/2 antibody) (Pharmigen), phosphoGSK3β
(1:2500) (Ser 9, anti-rabbit polyclonal phospho-GSK3β
antibody) (Cell Signalling Technology), total GSK3β
(1:2500) (anti-mouse monoclonal GSK3β antibody)
(Transduction Laboratories, Lexington, KY), phosphoAkt
(Thr308, anti-rabbit polyclonal phosphoAKT antibody)
(Calbiochem), total AKT (1:2500) (anti-rabbit polyclonal
AKT antibody), (Calbiochem), anti-mouse monoclonal
PI3K antibody(1:1000) (Transduction Labs), anti-rabbit
phospho-PKC (pan) that detects phosphorylation of PKC
isoforms α, β, δ, ε, and η (Cell Signalling Technology, Bev-
erly, MA) and anti-rabbit actin antibody (1:1000)
(Chemicon, San Diego, CA). Blots were incubated with
the HRP-tagged secondary antibody, detected with the
ECL reagent (DuPont NEN, Boston, MA), followed by
autoradiography. As a control, HUVEC were pre-treated
with one of the following pharmacological inhibitors:
MTA, LY294002, Gö6983, Bisindolymaleimide I, U0126
or PD98059 for 30 min and then FGF2 and gp120 were
added simultaneously. Cell viability was assayed 24 h
later.
Adenoviral constructs and transfection
Recombinant adenoviral constructs encoding constitu-
tively active (ca) forms of ERK and AKT were prepared as
previously described [53,54] (kindly provided by Dr.
Kazuhiko Namikawa, Asahikawa Medical College, Asa-
hikawa, Japan and Dr. Kenneth Walsh, Tufts University,
Boston, MA, respectively). Adenovirus encoding the green
fluorescent protein (GFP-Ad) as previously described [55]
was used as a control to account for any effects that may
be due to adenoviral infection. Briefly, for ca-ERK, cDNA
fragments containing the entire coding regions for human
MAP/ERK kinase 1 (MEK1) were isolated from human
embryonic kidney cells (HEK293) by PCR. ca-ERK lacks
the nuclear export signal (amino acids 32–51) and has
glutamic acid substitutions for two phosphorylation sites,
Ser218 and Ser222, was prepared by site-directed mutagene-
sis and fused to the hemagglutinin tag sequence, as
previously described [56]. ca-AKT, has the c-src myris-
toylation sequence fused in frame to the N-terminus of
the FLAG-AKT coding sequence [54]. High titer recom-
binant viral stocks (1011 plaque forming units) were gen-
erated in HEK293 cells and stored at -80°C. Endothelial
cells were plated at approximately 50% confluency inPage 12 of 15
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37°C, 5% CO2. HUVEC were changed to minimal media
(1% serum) for 6 h and then half of the media was
removed from each sample, pooled and stored at 37°C,
5% CO2. HUVEC were infected at a multiplicity of infec-
tion of 50 in pre-conditioned minimal media for 4 h,
achieving a 40–50% transduction efficiency (data not
shown). Minimal medium containing adenovirus was
replaced with pooled pre-conditioned minimal media
and cell cultures were further incubated for 48 h at 37°C
and 5% CO2. After 48 h, cells were treated with FGF2 (10
ng/ml) for 10 min, harvested in lysis buffer, stored at -
20°C, and later used for ERK and AKT kinase assays. For
immunocytochemistry, cells on coverslips were blocked
overnight at 4°C in 10% horse serum and 5% BSA. Cov-
erslips for ca-ERK were then labelled overnight at 4°C
with primary anti-Hemagglutinin (1:150) (Roche Diag-
nostics) and for ca-AKT with primary anti-FLAG (1:50)
(Sigma) followed by incubation with secondary bioti-
nylated IgG (Vector Laboratories) (1:200) for 1 h at room
temperature. Hemagglutinin and FLAG proteins were
detected with DAB (Sigma) and visualized by light micro-
scopy to access HA production. Experiments were con-
ducted at least three times to ensure reproducibility.
Immunocomplex kinase assays
ERK and AKT Assays were performed essentially as previ-
ously described with some modifications [57]. Briefly,
cells were rinsed twice with cold phosphate-buffered
saline and incubated for 20 min on ice in lysis buffer (1%
Triton X-100, 10 % glycerol, 50 mM HEPES, pH 7.4, 140
mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM phenyl-
methylsulfonylfluoride, 5 µg/ml aprotinin, 5 µg/ml leu-
peptin, 1 mM dithiothreitol). The cell lysates were then
centrifuged for 10 min at 14,000 rpm and protein concen-
tration was determined using the BCA reagent (Pierce,
Rockford, IL). Two hundred microliters of the supernatant
were pre-absorbed with a protein G-sepharose
(Amersham Pharmacia Biotech, Uppsala, Sweden) for 1 h
at 4°C. The pre-cleared lysates were incubated with 1 µg/
sample of anti-ERK monoclonal antibody (1:50)
(Pharmingen, San Diego, CA) or polyclonal anti-human
AKT antibody (anti-PKB 88–100) (Calbiochem) over-
night at 4°C, followed by incubation with protein G-
sepharose for 2 h at 4°C. After washing twice with the lysis
buffer and twice with a kinase buffer (20 mM HEPES, pH
7.2, 0.1 mM Na3VO4, 10 mM glycerophosphate, 10 mM
MgCl2, 1 mM dithiothreitol, 0.1 mM EGTA), the immune
complexes were incubated in 30 µl of the kinase buffer
containing 20 µg myelin basic protein for ERK (Sigma) or
1 µg of GSK3β fusion protein (Cell Signalling, Beverly,
MA) for AKT and 10 µCi of [γ-32P] ATP (6000 Ci/mmol,
PerkinElmer, Boston, MA) for 30 min at 30 °C. Reactions
were terminated by the addition of 5 µl of 500 mM EDTA
and 5 mM ATP. After adding 4× Laemmili SDS sample
buffer and boiling 5 min, samples were separated by 15%
SDS-PAGE, followed by autoradiography. Quantification
was performed with the PhosphorImager using the Image
Quant software (Molecular Dynamics, Sunnyvale, CA).
Statistical analysis
All experiments were performed in a blind code fashion.
After results were obtained, the code was broken and anal-
ysis was performed by utilizing one-way analysis of vari-
ance (ANOVA) with post hoc Dunnett's or Tukey-Kramer.
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